Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has earned a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $42.33.

A number of analysts recently weighed in on KROS shares. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. Scotiabank reduced their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday, January 16th. Wedbush lowered shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. Piper Sandler reduced their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, January 17th. Finally, William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th.

Keros Therapeutics Trading Up 0.6 %

Shares of NASDAQ:KROS opened at $11.08 on Monday. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The company has a 50-day moving average price of $12.52 and a 200 day moving average price of $39.49. The company has a market cap of $448.82 million, a price-to-earnings ratio of -2.13 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. As a group, equities analysts forecast that Keros Therapeutics will post -4.74 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors have recently bought and sold shares of the business. KBC Group NV increased its holdings in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares during the period. AlphaQuest LLC increased its holdings in Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after buying an additional 2,964 shares during the period. LMR Partners LLP purchased a new position in Keros Therapeutics during the third quarter valued at approximately $213,000. Finally, Victory Capital Management Inc. acquired a new stake in Keros Therapeutics in the third quarter valued at approximately $216,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.